Something went wrong with the connection!

Post Partum Depression Pipeline Insights: Upcoming Therapies Driving The PPD Market Forward

 Breaking News
  • No posts were found

Post Partum Depression Pipeline Insights: Upcoming Therapies Driving The PPD Market Forward

August 10
03:50 2020
Post Partum Depression Pipeline Insights: Upcoming Therapies Driving The PPD Market Forward

Post Partum Depression Pipeline

Postpartum Depression Pipeline Insight, 2020’ report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Postpartum Depression market.

Post Partum Depression: Disease Overview

Depression is one of the most common complications of pregnancy. During or after pregnancy, women’s body undergoes several kinds of changes, including physical appearances, appetite, sleeping patterns, hormonal, and so much more. It becomes common for women to experience anxiety, mood and alterations.

Postpartum Depression is a significant form of depression that persists for more than two weeks of delivery. In rare cases, in approximately 1-2% of women (affecting 1 or 2 in 1000 women post-childbirth), Postpartum depression worsens to Postpartum psychosis within 1-2 weeks post-delivery.

Visit to learn more: https://www.delveinsight.com/blog/postpartum-depression-market/

Post Partum Depression Pipeline

A detailed picture of the Postpartum Depression pipeline landscape is provided, which includes the disease overview and Postpartum Depression treatment guidelines. The assessment part of the report embraces in-depth Postpartum Depression commercial assessment and clinical assessment of the Postpartum Depression pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Postpartum Depression collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Know more about the report offerings: https://www.delveinsight.com/report-store/postpartum-depression-pipeline-insight

Post Partum Depression Marketed Therapies

Zulresso (brexanolone): Sage Therapeutics

Post Partum Depression Pipeline Therapies

Zuranolone (SAGE-217): Sage Therapeutics (Phase III)

Ganaxolone (CCD-1042): Marinus Pharmaceuticals (Phase II)

Request for free sample pages: https://www.delveinsight.com/sample-request/postpartum-depression-pipeline-insight

Scope of the report

  • The Postpartum Depression report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Postpartum Depression across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Postpartum Depression therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Postpartum Depression research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Postpartum Depression.

 

Table of Contents

1. Report Introduction

2. Postpartum Depression 

3. Postpartum Depression Current Treatment Patterns

4. Postpartum Depression – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Postpartum Depression Late Stage Products (Phase-III)

7. Postpartum Depression Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Postpartum Depression Discontinued Products

13. Postpartum Depression Product Profiles

14. Postpartum Depression Key Companies

15. Postpartum Depression Key Products

16. Dormant and Discontinued Products

17. Postpartum Depression Unmet Needs

18. Postpartum Depression Future Perspectives

19. Postpartum Depression Analyst Review  

20. Appendix

21. Report Methodology

 

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.

Browse through our vast repository from here.

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: www.delveinsight.com/

Related Articles